Engage Venture Partners

Engage Venture Partners is an Atlanta, Georgia-based collaborative innovation program and venture fund backed by Delta Air Lines, Invesco, Cox Enterprises, UPS, and The Home Depot. Founded in 2017 by Blake Patton, Marty Flanagan, and GP Bud Peterson, the firm connects early-stage enterprise technology startups with Fortune 500 corporations. Managed by Tech Square Ventures, the organization operates a startup growth accelerator and an $18 million fund to provide strategic capital and go-to-market acceleration for enterprise software developers. Across ten cohorts, the firm has built a portfolio of 75 companies that collectively employ over 3,000 people and have secured 116 customer contracts with corporate partners. These portfolio startups have raised two billion seven hundred million dollars in follow-on capital to scale their operations across the logistics, finance, transportation, and retail sectors throughout the Southeast.

# Engage Venture Partners: A Research-Driven Medtech Investment Platform

High-Level Overview

Engage Venture Partners is a research-driven venture capital firm headquartered in Minneapolis, Minnesota, with a specialized focus on early-stage medical technology companies[1][5]. The firm operates a distinctive SPV (Special Purpose Vehicle) investment model that enables accredited investors to co-invest alongside the fund in carefully vetted opportunities[3]. Rather than deploying capital through traditional fund structures, Engage leverages its extensive medtech expertise and networks to source investment opportunities aligned with its thesis, then invites its investor network to participate in individual deals that have passed rigorous due diligence[1][3].

The firm's investment philosophy centers on identifying medtech, digital health, and healthcare IT companies that address specific clinical needs with substantial market potential and clear regulatory pathways[1]. This targeted approach reflects a conviction that healthcare innovation requires not just capital, but deep domain expertise and operational support to navigate the complex regulatory landscape and achieve meaningful clinical adoption.

Core Differentiators

Specialized Investment Model: Engage's SPV-based approach differs fundamentally from traditional venture funds. Rather than committing capital to a blind pool, investors have visibility into specific opportunities and can choose which deals align with their investment thesis and risk tolerance[3]. This flexibility attracts a curated network of sophisticated investors while allowing the firm to maintain disciplined capital deployment.

Deep Medtech Expertise: The fund manager brings extensive experience executing over 75 deals across technology, healthcare, and consumer goods sectors, with particular strength in mid-market investments across North America and Europe[1]. This operational background enables the firm to provide more than capital—it offers strategic guidance on regulatory strategy, clinical validation, and market entry.

Data-Driven Approach: Engage emphasizes rigorous due diligence and a thematic, research-backed investment process rather than opportunistic deal-making[1]. This disciplined methodology helps the firm identify companies with genuine clinical differentiation and sustainable competitive advantages.

Network Leverage: The firm's investor network and medtech connections serve as a sourcing advantage, enabling early access to promising companies before they reach broader venture markets[3].

Role in the Broader Tech Landscape

Engage operates at the intersection of two powerful trends: the digitalization of healthcare and the maturation of venture capital's approach to specialized investing. The medtech sector has become increasingly attractive to venture investors as regulatory pathways have clarified, reimbursement models have evolved, and digital health has demonstrated real clinical and economic value.

The firm's SPV model also reflects a broader shift in venture capital toward transparency and investor choice. Rather than the traditional "trust us with your capital" model, Engage empowers investors with information and optionality—a trend gaining momentum as institutional LPs and high-net-worth individuals demand greater visibility into their investments.

By focusing exclusively on healthcare innovation, Engage positions itself to benefit from sustained tailwinds: aging populations, rising healthcare costs driving demand for efficiency, regulatory support for digital health solutions, and corporate partnerships seeking innovation[2]. The firm's track record includes investments in companies like Pleural Dynamics (Series A, $4.5M in March 2024) and Laplace Interventional (Series B, $12.9M in July 2023), demonstrating active deployment and co-investor confidence[5].

Quick Take & Future Outlook

Engage Venture Partners represents a niche but strategically positioned player in healthcare venture capital. The firm's combination of specialized expertise, disciplined investment process, and innovative SPV model positions it well to capture value in medtech's continued expansion. As healthcare systems increasingly prioritize digital transformation and cost containment, demand for the types of solutions Engage backs should remain robust.

The firm's future trajectory will likely depend on its ability to maintain deal flow quality, expand its investor network, and demonstrate strong returns from its portfolio companies. If Engage can consistently identify medtech companies that achieve meaningful clinical adoption and attractive exits, the SPV model could become increasingly attractive to both entrepreneurs seeking experienced healthcare investors and investors seeking curated deal access.

In an era where venture capital is becoming more specialized and transparent, Engage's focused approach and investor-friendly structure position it as a model for how traditional venture capital might evolve—combining deep domain expertise with greater investor agency and alignment.